Valneva (VALN) has released an update.
Valneva SE has appointed Dr. Hanneke Schuitemaker as its new Chief Scientific Officer to enhance its R&D strategy and support its mission to provide innovative vaccine solutions for infectious diseases. Dr. Schuitemaker, with over 20 years in vaccine research including her role at Johnson & Johnson, brings extensive experience to Valneva as they focus on developing their pipeline, including clinical programs for Lyme disease and the chikungunya virus. Valneva aims to leverage its commercial success with approved vaccines to further fuel R&D progress.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
